BioSpace News Archive

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx® SuperSaturated Oxygen Therapy will be highlighted at the upcoming Transcatheter Cardiovascular Therapeutics annual scientific meeting November 4-6 in Orlando, Florida.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced initial safety and efficacy findings from its Phase 1b/2 study of IMGN632 in combination with Vidaza® and Venclexta® in patients with relapsed/refractory acute myeloid leukemia.

BeiGene announced clinical results and real world data from its hematology program to be presented at the 63rd American Society of Hematology Annual Meeting and Exposition, including two oral presentations on the Phase 3 SEQUOIA trial comparing BRUKINSA® to bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

bluebird bio, Inc. announced that new data from its lentiviral vector gene addition programs for patients with β-thalassemia who require regular red blood cell transfusions and sickle cell disease will be presented at the 63rd American Society of Hematology Annual Meeting and Exposition, taking place December 11-14, 2021, at the Georgia World Congress Center in Atlanta, Georgia, and virtually.

Xencor, Inc. today announced that updated clinical data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell malignancies will be presented in a poster session during the 63rd American Society Annual Meeting

Ambu Inc., the world leader in single-use endoscopy, announced that an Ohio gastroenterologist has become the first physician in the U.S. to use Ambu’s new sterile, single-use duodenoscope in 100 endoscopic retrograde cholangiopancreatography procedures.

Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition

Rheos Medicines today announced it will present preclinical data showing the potential for MALT1 inhibitors for the treatment of chronic Graft-Versus-Host Disease (GVHD) at the 63rd Annual Meeting of the American Society of Hematology (ASH)

Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition

World’s First Controlled Study to Investigate Ketamine-Assisted Psychotherapy.